India's RFCL Braves Into The Stronghold Of MNCs With High-end Diagnostics; Will It Become The Next Takeover Candidate?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Having identified a distinct cost advantage over its bigger Western counterparts, RFCL - India's largest in-vitro diagnostics and laboratory solutions firm - is branching out into the manufacture of high-end diagnostic products used for immunoassays, a range of molecular diagnostic kits and theranostics, bringing it a step closer toward personalized medicine
You may also be interested in...
After Buying Vetnex, Pfizer Invests $40 Million To Set Up Discovery Research Center For Animal Health Drugs In India
MUMBAI - When Pfizer's $3.5 billion animal health unit made a resolute bid last June to acquire Vetnex - a small but growing Indian veterinary care company - it took industry watchers by surprise, but a well-crafted, elaborate plan was stealthily being executed
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).